I'm not greedy, I'd settle for 100/share. LOL

I think the guy who wrote that article was holding back on share price estimates because it does sound unbelievable. But, remember JAZZ -- was trading at 20 cents for a long time, they went up 7000% (yes seven THOUSAND percent) in the space of 2 years.  Its high for the year was 60 -- closed at 56.69 on Friday -- not bad for a 20 cent stock, huh?

http://www.marketwatch.com/investing/stock/JAZZ/profile

The company has diverse portfolio of products in the areas of narcolepsy, pain, psychiatry and women's health. Its product portfolio includes: XYREM, PRIALT, FAZACLO LD & HD, LUVOX CR, ELESTRIN, AVCTM CREAM, NATELLE ONE, GESTICARE DHA, URELLE, GASTROCROM, NIRAVAM and PARCOPA. The company's Xyrem product is used for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy and Luvox CR product is marketed for the treatment of obsessive compulsive disorder. Its JZP-6 product is for the treatment of fibromyalgia, while JZP-8 is for the treatment of acute repetitive seizures in epilepsy. The company builds its portfolio of products through a combination of internal development, acquisition and in-licensing activities. Jazz Pharmaceuticals was founded on January 18, 2012 and is headquartered in Dublin, Ireland.